Stock Track | Ultragenyx Pharmaceutical Stock Soars on Analyst's Bullish Report

Stock Track

2024/11/11

Shares of Ultragenyx Pharmaceutical (RARE) surged 5.11% on November 11th, 2024, after a bullish analyst report from TD Cowen.

Analyst Yaron Werber maintained a Buy rating on Ultragenyx and reiterated his positive outlook on the biopharmaceutical company. While the exact details of the report were not disclosed, Werber's bullish stance seems to have fueled investor confidence in Ultragenyx, driving the stock price higher.

Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. The company has several promising drug candidates in its pipeline, and Werber's report likely highlighted the potential for these therapies to drive future growth and profitability for the company.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1138244085"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1138244085\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1138244085?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138244085","market":"us","top_or_hot":-1,"title":"Stock Track | Ultragenyx Pharmaceutical Stock Soars on Analyst's Bullish Report","media":"Stock Track","content":"<p>Shares of Ultragenyx Pharmaceutical (RARE) surged 5.11% on November 11th, 2024, after a bullish analyst report from TD Cowen.</p>\n\n<p>Analyst Yaron Werber maintained a Buy rating on Ultragenyx and reiterated his positive outlook on the biopharmaceutical company. While the exact details of the report were not disclosed, Werber's bullish stance seems to have fueled investor confidence in Ultragenyx, driving the stock price higher.</p>\n\n<p>Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. The company has several promising drug candidates in its pipeline, and Werber's report likely highlighted the potential for these therapies to drive future growth and profitability for the company.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ultragenyx Pharmaceutical Stock Soars on Analyst's Bullish Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ultragenyx Pharmaceutical Stock Soars on Analyst's Bullish Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-11 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Ultragenyx Pharmaceutical (RARE) surged 5.11% on November 11th, 2024, after a bullish analyst report from TD Cowen.</p>\n\n<p>Analyst Yaron Werber maintained a Buy rating on Ultragenyx and reiterated his positive outlook on the biopharmaceutical company. While the exact details of the report were not disclosed, Werber's bullish stance seems to have fueled investor confidence in Ultragenyx, driving the stock price higher.</p>\n\n<p>Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. The company has several promising drug candidates in its pipeline, and Werber's report likely highlighted the potential for these therapies to drive future growth and profitability for the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RARE","symbol_name":"Ultragenyx Pharmaceutical Inc","start_time":0,"source_url":"","article_id":"1138244085","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138244085","pubTimestamp":1731338922,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ultragenyx Pharmaceutical  surged 5.11% on November 11th, 2024, after a bullish analyst report from TD Cowen.Analyst Yaron Werber maintained a Buy rating on Ultragenyx and reiterated his positive outlook on the biopharmaceutical company. While the exact details of the report were not disclosed, Werber's bullish stance seems to have fueled investor confidence in Ultragenyx, driving the stock price higher.Ultragenyx is a biopharmaceutical company focused on developing treatments for rare","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RARE":"Ultragenyx Pharmaceutical Inc"},"translate_title":"股票轨迹Ultragenyx Pharmaceutical股票因分析师看涨报告而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":1},"content_text":"Shares of Ultragenyx Pharmaceutical (RARE) surged 5.11% on November 11th, 2024, after a bullish analyst report from TD Cowen.\nAnalyst Yaron Werber maintained a Buy rating on Ultragenyx and reiterated his positive outlook on the biopharmaceutical company. While the exact details of the report were not disclosed, Werber's bullish stance seems to have fueled investor confidence in Ultragenyx, driving the stock price higher.\nUltragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. The company has several promising drug candidates in its pipeline, and Werber's report likely highlighted the potential for these therapies to drive future growth and profitability for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}